1、2025 Biomedtracker Datamonitor Healthcare Post-ADA ReportJuly 2025Brought to you by:Summary The American Diabetes Association(ADA)85th Scientific Sessions was held in Chicago,Illinois from June 20-June 23,2025 and featured the latest data from current therapeutic interventions and drug candidates fo

2、r type 1 and type 2 diabetes,and obesity.Key data presented included the latest results of numerous glucagon-like peptide 1(GLP-1)-based therapies for type II diabetes and obesity.This post-meeting report features commentary from our analysts on specific presentations.It also includes a compilation

3、of data events added in conjunction with the meeting.About the Author Biomedtracker is an independent research service that offers proprietary clinical assessments and patient-based revenue forecasts of developmental drugs within a comprehensive and intuitive drug information database.Clients from t

4、he pharmaceutical,biotech,and investment industries rely on Biomedtracker for its insight on the likelihood of approval,commercial potential,and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.Over the last several years,Biome

5、dtracker has become the leader in providing objective information alongside evidence based clinical assessments and investment research on pipeline drugs worldwide.For more information on getting direct access to Biomedtracker,please email .Disclaimer Copyright 2025 Evaluate,a Norstella company This

6、 report is published by Evaluate(the Publisher).This report contains information from reputable sources and although reasonable efforts have been made to publish accurate information,you assume sole responsibility for the selection,suitability and use of this report and acknowledge that the Publishe